Published in Drug Week, July 2nd, 2004
The trial, known as EARLY ACS (early glycoprotein IIb-IIIa inhibition in non-st-segment elevation acute coronary syndrome: a randomized, placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-st-segment elevation acute coronary syndrome) will evaluate the benefit of INTEGRILIN compared to placebo in reducing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.